DE60209704D1 - Neue kristallforme von azithromycin - Google Patents

Neue kristallforme von azithromycin

Info

Publication number
DE60209704D1
DE60209704D1 DE60209704T DE60209704T DE60209704D1 DE 60209704 D1 DE60209704 D1 DE 60209704D1 DE 60209704 T DE60209704 T DE 60209704T DE 60209704 T DE60209704 T DE 60209704T DE 60209704 D1 DE60209704 D1 DE 60209704D1
Authority
DE
Germany
Prior art keywords
azithromycin
crystal form
new crystal
new
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60209704T
Other languages
English (en)
Other versions
DE60209704T2 (de
Inventor
Jane Li
Vincent Trask
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60209704(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE60209704D1 publication Critical patent/DE60209704D1/de
Application granted granted Critical
Publication of DE60209704T2 publication Critical patent/DE60209704T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
DE60209704T 2001-05-22 2002-05-01 Neue kristallforme von azithromycin Revoked DE60209704T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US29256501P 2001-05-22 2001-05-22
US292565P 2001-05-22
US29774101P 2001-06-12 2001-06-12
US297741P 2001-06-12
US34304101P 2001-12-21 2001-12-21
US343041P 2001-12-21
PCT/IB2002/001570 WO2002094843A1 (en) 2001-05-22 2002-05-01 Crystal forms of azithromycin

Publications (2)

Publication Number Publication Date
DE60209704D1 true DE60209704D1 (de) 2006-05-04
DE60209704T2 DE60209704T2 (de) 2006-11-16

Family

ID=27404135

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60209704T Revoked DE60209704T2 (de) 2001-05-22 2002-05-01 Neue kristallforme von azithromycin
DE60228345T Expired - Lifetime DE60228345D1 (de) 2001-05-22 2002-05-01 Neue Kristallforme von Azithromycin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60228345T Expired - Lifetime DE60228345D1 (de) 2001-05-22 2002-05-01 Neue Kristallforme von Azithromycin

Country Status (35)

Country Link
US (10) US6977243B2 (de)
EP (1) EP1390377B1 (de)
JP (3) JP2004530703A (de)
KR (1) KR100574153B1 (de)
AP (1) AP2003002906A0 (de)
AR (1) AR036022A1 (de)
AT (2) ATE319730T1 (de)
AU (1) AU2002256846B2 (de)
BG (1) BG108370A (de)
BR (1) BR0209918A (de)
CA (1) CA2391659C (de)
CR (1) CR7159A (de)
CZ (1) CZ20033154A3 (de)
DE (2) DE60209704T2 (de)
DK (1) DK1390377T3 (de)
EA (2) EA007618B1 (de)
EE (1) EE200300575A (de)
ES (2) ES2258142T3 (de)
GE (1) GEP20084399B (de)
HU (1) HUP0400446A2 (de)
IL (1) IL158591A0 (de)
IS (1) IS7007A (de)
MA (1) MA27023A1 (de)
MX (1) MXPA03010028A (de)
MY (1) MY129319A (de)
NO (2) NO321894B1 (de)
NZ (2) NZ529118A (de)
PA (1) PA8545701A1 (de)
PE (1) PE20021064A1 (de)
PL (1) PL367091A1 (de)
PT (1) PT1390377E (de)
SK (1) SK14402003A3 (de)
TN (1) TNSN03121A1 (de)
WO (1) WO2002094843A1 (de)
YU (1) YU91603A (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
IL143376A0 (en) * 1998-11-30 2002-04-21 Teva Pharma Ethanolate of azithromycin, process for the manufacture, and pharmaceutical compositions thereof
CA2419873A1 (en) * 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
KR100431431B1 (ko) * 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
BR0209918A (pt) * 2001-05-22 2004-03-30 Pfizer Prod Inc Formas cristalinas da azitromicina
ITMI20011762A1 (it) 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
WO2003053416A1 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Directly compressible formulations of azithromycin
MXPA04003027A (es) * 2001-12-21 2004-07-05 Pfizer Prod Inc Metodos para granulacion humeda de azitromicina.
CA2474809A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Dry granulated formulations of azithromycin
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
CA2422972A1 (en) * 2003-03-21 2004-09-21 Apotex Inc. Isopropanolate of azithromycin and method of manufacturing
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1648473B1 (de) 2003-07-24 2009-01-28 PLIVA HRVATSKA d.o.o. Schnellösliches azithromycin in einzeldosisform
EP1878432A1 (de) * 2003-07-24 2008-01-16 Pliva - Research and Development Ltd. Schnellösliches Azithromycin in Einzeldosisform
AU2004311544A1 (en) * 2003-11-17 2005-07-21 Merck & Cie Crystalline forms of (6R) -L-erythro-tetrahydrobiopterin dihydrochloride
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20050250714A1 (en) * 2004-05-06 2005-11-10 Lin Kangwen L Crystalline forms of 9-(S)-erythromycylamine
US20070249827A1 (en) * 2004-06-02 2007-10-25 Sandoz Ag Meropenem Intermediatein in Crystalling Form
US7683162B2 (en) 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
US8495244B2 (en) * 2005-06-29 2013-07-23 Jumpstart Wireless Corporation System and method for dynamic automatic communication path selection, distributed device synchronization and task delegation
EP1910393A2 (de) * 2005-07-05 2008-04-16 Hetero Drugs Limited Neues verfahren zur herstellung von didanosin unter verwendung neuer zwischenprodukte
EP1904510A1 (de) * 2005-07-14 2008-04-02 Pfizer Products Incorporated Verfahren zur bildung amorpher azithromycinpartikel
CN101287706A (zh) * 2005-09-21 2008-10-15 尼科梅德有限责任公司 作为组蛋白脱乙酰基酶抑制剂的磺酰基吡咯盐酸盐
JP2009513702A (ja) * 2005-10-31 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペラジニルおよびジアザパニルベンズアミド誘導体の新規な製造方法
US8558765B2 (en) * 2005-11-07 2013-10-15 Global Oled Technology Llc Method and apparatus for uniformity and brightness correction in an electroluminescent display
US8299095B2 (en) * 2006-06-16 2012-10-30 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition and uses thereof
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
CN102382113B (zh) * 2006-10-27 2016-04-06 西格诺药品有限公司 包含用于治疗疾病或紊乱的化合物的固体形式，其组合物，及其用途
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
US7919676B2 (en) 2007-08-03 2011-04-05 Pioneer Hi-Bred International, Inc. Msca1 nucleotide sequences impacting plant male fertility and method of using same
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
EP2085397A1 (de) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Kristalline Form von Abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
US8216363B2 (en) * 2008-10-27 2012-07-10 Illinois Institute Of Technology Continuous antisolvent crystallization process and system using plug flow reactors
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
EA201101319A1 (ru) 2009-03-13 2012-04-30 Да Волтерра Композиции и способы элиминации грамотрицательных бактерий
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
CN107445919A (zh) 2010-03-12 2017-12-08 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
SG10201506865WA (en) * 2010-09-01 2015-10-29 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
US9174973B2 (en) * 2011-09-30 2015-11-03 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
RU2017134509A (ru) 2015-04-24 2019-04-04 Омерос Корпорейшн Ингибиторы pde10 и соответствующие композиции и способы
EP3108879A1 (de) 2015-06-25 2016-12-28 Cassiopea S.p.A. Hochkonzentrierte formulierung
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43116B (en) 1979-04-02 1989-04-30 Pliva Pharm & Chem Works Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox
SI8110592A8 (en) 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4465674A (en) 1983-09-06 1984-08-14 Pfizer Inc. Azahomoerythromycin D derivative and intermediates therefor
MX12213A (es) * 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
WO1989002271A1 (en) 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US4983531A (en) * 1990-02-12 1991-01-08 Motorola, Inc. Method of fabricating a single polysilicon bipolar transistor which is compatible with a method of fabricating CMOS transistors
CN1093370A (zh) * 1993-12-10 1994-10-12 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
CN1034734C (zh) 1993-12-10 1997-04-30 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
KR100524214B1 (ko) * 1996-07-29 2005-11-01 아보트 러보러터리즈 클라리트로마이신의 제2 결정형의 제조 방법
CN1161971A (zh) 1997-01-03 1997-10-15 石家庄制药集团有限公司 一种阿齐霉素结晶及其制备方法
PT102130A (pt) 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A Processo de preparacao de dihidrato de azitromicina
TW546302B (en) 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
IL143376A0 (en) * 1998-11-30 2002-04-21 Teva Pharma Ethanolate of azithromycin, process for the manufacture, and pharmaceutical compositions thereof
AU5820400A (en) * 1999-06-29 2001-01-31 Biochemie S.A. Macrolides
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
PT1246831E (pt) 2000-01-04 2008-03-28 Teva Pharma Método de preparação de di-hidrato de azitromicina
ES2162764B1 (es) 2000-05-17 2003-04-01 Ercros Ind Sa Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
WO2002007736A1 (en) 2000-07-24 2002-01-31 Cadila Pharmaceuticals Limited The process for manufacturing of clear liquid pharmaceutical composition of azithromycin
DE60026718T2 (de) 2000-07-25 2006-11-16 Laboratorio Silanes, S.A. De C.V. Einstufiges verfahren zur herstellung von 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle(11.2.11)hexadeca-1(2)-en-8-ona undeine neue form von 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin a
ITBO20000471A1 (it) 2000-07-31 2002-01-31 Vieri Ridolfi Dispositivo di supporto per prodotti da fumo particolarmente sigarette .
ES2172417B1 (es) 2000-07-31 2003-09-16 Sint Quimica Sa Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
AU2001214115A1 (en) 2000-08-01 2002-02-13 Habil F. Khorakiwala Process for the preparation of anhydrous azithromycin
CA2419873A1 (en) 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
SK287814B6 (sk) 2000-11-27 2011-11-04 Sandoz Ag Azithromycin in the form of a monohydrate, a process for its preparation and pharmaceutical compositions comprising same
IN190080B (de) 2001-01-29 2003-06-07 Alembic Ltd
KR100431431B1 (ko) 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
BR0209918A (pt) * 2001-05-22 2004-03-30 Pfizer Prod Inc Formas cristalinas da azitromicina
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US6764997B2 (en) 2001-10-18 2004-07-20 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions

Also Published As

Publication number Publication date
CR7159A (es) 2004-02-23
US20040043945A1 (en) 2004-03-04
YU91603A (sh) 2006-08-17
US7105179B2 (en) 2006-09-12
NZ529118A (en) 2005-10-28
EP1390377B1 (de) 2006-03-08
US20050245469A1 (en) 2005-11-03
JP2007161726A (ja) 2007-06-28
JP2006152002A (ja) 2006-06-15
CA2391659C (en) 2006-05-30
IS7007A (is) 2003-10-30
US6977243B2 (en) 2005-12-20
HUP0400446A2 (hu) 2004-09-28
AU2002256846B2 (en) 2007-04-05
ES2258142T3 (es) 2006-08-16
IL158591A0 (en) 2004-05-12
US20040082527A1 (en) 2004-04-29
TNSN03121A1 (en) 2005-12-23
EA200500630A1 (ru) 2006-02-24
EA009611B1 (ru) 2008-02-28
KR20040014525A (ko) 2004-02-14
CZ20033154A3 (en) 2004-04-14
EA007618B1 (ru) 2006-12-29
EP1390377A1 (de) 2004-02-25
NZ539801A (en) 2006-10-27
PE20021064A1 (es) 2002-11-21
ATE404575T1 (de) 2008-08-15
GEP20084399B (en) 2008-06-10
US7053192B2 (en) 2006-05-30
BR0209918A (pt) 2004-03-30
US7081525B2 (en) 2006-07-25
DE60228345D1 (de) 2008-09-25
US20040138149A1 (en) 2004-07-15
US7307156B2 (en) 2007-12-11
JP4584162B2 (ja) 2010-11-17
ATE319730T1 (de) 2006-03-15
CA2391659A1 (en) 2002-11-22
KR100574153B1 (ko) 2006-04-25
BG108370A (bg) 2004-11-30
US20040043944A1 (en) 2004-03-04
ES2310886T3 (es) 2009-01-16
PA8545701A1 (es) 2003-09-05
US20050192234A1 (en) 2005-09-01
PL367091A1 (en) 2005-02-21
AR036022A1 (es) 2004-08-04
SK14402003A3 (sk) 2004-06-08
NO321894B1 (no) 2006-07-17
US7309782B2 (en) 2007-12-18
JP2004530703A (ja) 2004-10-07
WO2002094843A1 (en) 2002-11-28
DE60209704T2 (de) 2006-11-16
PT1390377E (pt) 2006-06-30
EA200301115A1 (ru) 2004-04-29
US20050256063A1 (en) 2005-11-17
MY129319A (en) 2007-03-30
NO20035177D0 (no) 2003-11-21
NO20061049L (no) 2003-05-12
EE200300575A (et) 2004-04-15
AP2003002906A0 (en) 2003-12-31
US20050256062A1 (en) 2005-11-17
MA27023A1 (fr) 2004-12-20
US7282486B2 (en) 2007-10-16
DK1390377T3 (da) 2006-06-19
MXPA03010028A (es) 2004-02-12
US20030162730A1 (en) 2003-08-28
US20050090459A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
DE60209704D1 (de) Neue kristallforme von azithromycin
DE60236581D1 (de) Ng von mosaikeffekten
DE60211601D1 (de) Bereitstellung von positionsabhängigen Inhalten
DE02784674T1 (de) Quantifizierung von polypeptiden
DE50212455D1 (de) Verwendung von Dimerdiolen
DK1440083T3 (da) Molekyler
DE60219386D1 (de) Flüssigkristallanzeige
DE60234074D1 (de) Flüssigkristallanzeige
DE60227828D1 (de) E von schmelzkleber
DE60111435D1 (de) Flüssigkeitskühlung von Glasformen
DK1451433T3 (da) Glassammensætning
DE60031450D1 (de) Polymorph v von torasemid
DE60007360T2 (de) Amorphe modifikation von torasemid
ATE293113T1 (de) Neue polymorphe formen von olanzapin
DE50109358D1 (de) Flüssigkristall-Anzeige
DE50203067D1 (de) Quarzoszillatorschaltung
AT503224A3 (de) Holzbautafel
DE60208824D1 (de) Verbesserungen von elektromechanischen aktuatoren
DE60217710D1 (de) Neue formulierung
ATA5002002A (de) Vibrator
DE60211186D1 (de) Neue verwendung substituierter aminomethylchromane
DE60206043D1 (de) Neue indolderivate
DE60223782D1 (de) Kombination von Frontplatten
DE60216986D1 (de) Neue verwendung von pipatalin
DE50203046D1 (de) Verwendung von Esterquats

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation